Dobutamine Hydrochloride Injection Shortage: FDA Report
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
The FDA reports a current shortage of certain presentations of Dobutamine Hydrochloride Injection, with some manufacturers facing availability issues due to manufacturing delays.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 7, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Dobutamine Hydrochloride Injection.
What's in Shortage
The drug in shortage is Dobutamine Hydrochloride Injection, with brand names including DOBUTAMINE, DOBUTAMINE IN DEXTROSE, and DOBUTAMINE HYDROCHLORIDE IN DEXTROSE. It is available in injection dosage form and falls under the therapeutic categories of Cardiovascular, Pediatric, and Renal. The shortage status is current, with the initial posting date of November 6, 2017, and last updated on March 27, 2026.
Which Manufacturers Are Affected
- Hospira, Inc., a Pfizer Company: For the presentation Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-01), it is available. Contact info: 844-646-4398.
For Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 500 mg/250mL (200 mg/mL) (NDC 0409-2347-32), it is unavailable, with next delivery in April 2026 and estimated recovery in June 2026 due to manufacturing delay. Contact info: 844-646-4398.
For Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-02), it is available. Contact info: 844-646-4398.
For Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 250 mg/250mL (100 mg/mL) (NDC 0409-2346-32), it is unavailable, with next delivery in April 2026 and estimated recovery in June 2026 due to manufacturing delay. Contact info: 844-646-4398.
For Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-88), it is unavailable, with next delivery and estimated recovery in December 2027 due to manufacturing delay. Contact info: 844-646-4398.
For Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1,000 mg/250mL (400 mg/mL) (NDC 0409-3724-32), it is unavailable, with next delivery in April 2026 and estimated recovery in June 2026 due to manufacturing delay. Contact info: 844-646-4398. - Baxter Healthcare: For Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 200 mg/100 mL (NDC 0338-1075-02), it is available. Contact info: 888-229-0001.
For Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/100 mL (NDC 0338-1077-02), it is available. Contact info: 888-229-0001.
For Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 100 mg/100 mL (NDC 0338-1073-02), it is available. Contact info: 888-229-0001.
Why There's a Shortage
The shortage for the affected presentations from Hospira, Inc., a Pfizer Company is due to manufacturing delays, as reported by the manufacturer. No specific reason was provided for other manufacturers.
What Patients Should Do
Patients who rely on Dobutamine Hydrochloride Injection should speak with their pharmacist to check availability and discuss options. They may also contact the relevant manufacturer using the provided contact information for updates. Remember, patients should consult their healthcare provider for any guidance on their treatment; this article does not provide medical advice.
Source
This information is sourced from the FDA Drug Shortage Database, with the shortage initially posted on November 6, 2017, and last updated on March 27, 2026.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA drug-shortage notice: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (3,137 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to April 7, 2026.
Frequently Asked Questions
Common questions about this FDA drug-shortage notice.